Rhenovia Obtains Significant Research Contract with the US National Institutes of Health
News Jul 30, 2009
Rhenovia Pharma SAS, a biopharmaceutical company specialized in the development and optimization of drugs for Alzheimer's and other diseases of the brain, announces that it has signed a 4-year contract with the University of Southern California (USC) and the NIH.
The contract is part of a Bioengineering Research Partnership Program awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the US National Institutes of Health.
Rhenovia Pharma will be partnered by two laboratories of the University of Southern California, Los Angeles (USC). These are the Laboratory of Biological Sciences (LAS) under Dr Michel Baudry and the Laboratory of Biomedical Engineering (VSoE) under Dr Theodore Berger.
The three partners will receive a total amount of USD 2.3 million (EUR 1.65 million) in support of their research programs. Rhenovia will perform a service partnership activity as subcontractor and will receive USD 440,000.
The program associates two prestigious academic groups with a fast growing drug discovery start up in a joint effort to gain understanding of the cellular mechanisms that underly brain functions and diseases, and to develop technological tools facilitating the discovery and development of new therapeutic agents to treat brain diseases.
The objective of the academic groups is to intensify the development of unique mathematical modeling and computer simulation tools to systematically explore molecular processes relevant to diseases of the brain. These include the processes underlying glutamatergic synaptic transmission, and the effects of these synaptic processes on multi-synaptic cellular dynamics, and ultimately on a small network of hippocampal neurons.
Using its experience of the pharmaceutical industry and its expertise in drug discovery, Rhenovia will have the task of integrating the cellular and molecular mechanisms that serve as drug targets into these mathematical models and to perform the optimization and validations needed for their commercial application.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE